Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer.
Fiche publication
Date publication
décembre 2018
Journal
Oncotarget
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine, Dr BOREL Christian, Dr GUIHARD Sébastien, Dr JUNG Alain, Pr PETIT Thierry, Dr THIERY Alicia, Dr DEMARCHI Martin, Dr COLIAT Pierre, Dr BURGY Mickaël
Tous les auteurs :
Borel C, Regnier-Gavier O, Carinato H, Guihard S, Antoni D, Demarchi M, Sirlin F, Exinger D, Petit-Jean E, Thiery A, Bronner G, Schultz P, Flesch H, Frasie V, Prébay D, Petit T, Jung AC, Burgy M, Coliat P
Lien Pubmed
Résumé
The EXTREME protocol is the standard of care for recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC) in first line. Beyond the first-line except immunotherapy, poor efficacy was reported by second-line chemotherapy. Re-challenge strategies based on a repetition of the first line with platinum and cetuximab regimens might have been an option to consider.
Mots clés
EXTREME, HNSCC, platinum free Interval, re-challenge
Référence
Oncotarget. 2018 Dec 25;9(101):37581-37588